Is navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis?

Anti-Cancer Drugs

Volumn 6, Issue SUPPL. 1, 1995, Pages 15-21

  Marty, M ^a   Kleisbauer, J P ^a   Fournel, P ^a   Vergnenegre, A ^a   Carles, P ^a   Loria Kanza, Y ^a   Simonetta, C ^a   De Bruijn, K M ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Emesis; Nausea; Navoban (tropisetron); Vomiting; Zofran (ondansetron)

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; ONDANSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; TROPISETRON; ANTIEMETIC AGENT; INDOLE DERIVATIVE;

ADULT; ANTIEMETIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MIDDLE AGED; NAUSEA; NEOPLASM;

ANTIEMETICS; CISPLATIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; VOMITING;

EID: 85047671053     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199502001-00004     Document Type: Conference Paper

References (0)